0B68 Pro, Barbara - Thomas Jefferson University - Thomas Jefferson University
bxp022

Barbara Pro, MD

Contact Dr. Pro

925 Chestnut Street
Suite 420A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Current management of peripheral t-cell lymphomas
  2. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  3. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: An open label, single arm, phase II trial
  4. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: Results of a phase i study
  5. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins
  6. Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)
  7. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
  8. The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: A retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)
  9. Paclitaxel, topotecan and rituximab: Long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
  10. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
  11. Peripheral T-cell lymphomas: A review of current approaches and hopes for the future
  12. Phase i study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma
  13. Racial differences in chronic lymphocytic leukemia: Digging deeper
  14. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
  15. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial
  16. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma
  17. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas
  18. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: A prospective, randomized controlled phase III trial
  19. Non-Hodgkin's lymphomas, version 1.2013: Featured updates to the NCCN guidelines
  20. Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma
0